{
    "filename": "0001193125-25-220480_primary_doc.xml",
    "path": "d:\\Files\\Code\\Funkles-SEC\\FunklesScraper\\..\\filings_cache\\0001193125-25-220480_primary_doc.xml",
    "date": "2025-09-26",
    "form": "SCHEDULE 13D",
    "file_type": "SCHEDULE 13D",
    "original_filename": "primary_doc.xml",
    "accession": "0001193125-25-220480",
    "cik": "0001584541",
    "label": "Plans to influence or control the company",
    "summary": "Scilex Holding Company (SHC) and its subsidiary Scilex, Inc. reported their beneficial ownership in Semnur Pharmaceuticals, Inc. following a business combination on September 22, 2025. SHC now beneficially owns 188,554,849 shares, representing 79.89% of the Common Stock, and 100% of the Series A Preferred Stock, totaling 80.34% of the issuer's aggregate voting power. This significant ownership was established through the merger, debt conversions, and other share acquisitions, and SHC also secured substantial control rights through a Stockholder Agreement. Post-merger, on September 23, 2025, SHC and Scilex, Inc. collectively sold 12,500,000 common shares to Biconomy PTE.LTD for Bitcoin.",
    "share %": null
}